By making RNA that governs protein synthesis the drug discovery target, we will provide drugs that offer a new approach to diseases that until now have proved difficult to treat.

Our proprietary drug discovery platform is capable of creating therapeutic drugs for various diseases regardless of the mode of inheritance, and we are developing our pipeline based on unmet medical needs.